title: Positron emission tomography with [18F]flutemetamol and [11C]PiB for in vivo detection of cerebral cortical amyloid in normal pressure hydrocephalus patients.
abstract: OBJECTIVE
  This study determined the correlation between uptake of the amyloid positron emission tomography (PET) imaging agent [(18) F]flutemetamol and amyloid-β measured by immunohistochemical and histochemical staining in a frontal cortical biopsy.
  
  
  METHODS
  Fifteen patients with possible normal pressure hydrocephalus (NPH) and previous brain biopsy obtained during intracranial pressure monitoring underwent [18F]flutemetamol PET. Seven of these patients also underwent [11C] Pittsburgh compound B (PiB) PET. [18F]Flutemetamol and [11C]PiB uptake was quantified using standardized uptake value ratio (SUVR) with the cerebellar cortex as a reference region. Tissue amyloid-β was evaluated using the monoclonal antibody 4G8, Thioflavin-S and Bielschowsky silver stain.
  
  
  RESULTS
  [18F]Flutemetamol and [11C]PiB SUVRs correlated with biopsy specimen amyloid-β levels contralateral (r = 0.86, P < 0.0001; r = 0.96, P = 0.0008) and ipsilateral (r = 0.82, P = 0.0002; r = 0.87, P = 0.01) to the biopsy site. Association between cortical composite [(18) F]flutemetamol SUVRs and [11C]PiB SUVRs was highly significant (r = 0.97, P = 0.0003).
  
  
  CONCLUSIONS
  [18F]Flutemetamol detects brain amyloid-β in vivo with moderate to high sensitivity and high specificity. This agent, therefore, represents a valuable new tool to study and verify the presence of amyloid-β pathology, both in patients with possible NPH and among the wider population.
authors: Department of Neurosurgery, KUH NeuroCenter, Kuopio University Hospital and Neurosurgery, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland. ville.leinonen@kuh.fi
authors: V
authors: V
authors: Leinonen
authors: J O
authors: JO
authors: Rinne
authors: K A
authors: KA
authors: Virtanen
authors: O
authors: O
authors: Eskola
authors: J
authors: J
authors: Rummukainen
authors: J
authors: J
authors: Huttunen
authors: M
authors: M
authors: von Und Zu Fraunberg
authors: O
authors: O
authors: Nerg
authors: A M
authors: AM
authors: Koivisto
authors: J
authors: J
authors: Rinne
authors: J E
authors: JE
authors: Jääskeläinen
authors: C
authors: C
authors: Buckley
authors: A
authors: A
authors: Smith
authors: P A
authors: PA
authors: Jones
authors: P
authors: P
authors: Sherwin
authors: G
authors: G
authors: Farrar
authors: R
authors: R
authors: McLain
authors: M
authors: M
authors: Kailajärvi
authors: K
authors: K
authors: Heurling
authors: I D
authors: ID
authors: Grachev
mesh_terms: D000368:Aged; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000814:Aniline Compounds / Q000009:adverse effects; D052160:Benzothiazoles / Q000009:adverse effects; D001706:Biopsy; D002540:Cerebral Cortex / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D059907:Functional Neuroimaging; D006801:Humans; D006850:Hydrocephalus, Normal Pressure / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology*; D008297:Male; D058225:Plaque, Amyloid / Q000473:pathology; D011877:Radionuclide Imaging; D012680:Sensitivity and Specificity; D013844:Thiazoles
chemical_list: C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D016229:Amyloid beta-Peptides; D000814:Aniline Compounds; D052160:Benzothiazoles; D013844:Thiazoles; C581552:flutemetamol